Scientology Ideal Org Rises Like a Legendary King Wave in Ventura’s Surf City

Some 4,000 Scientologists and federal, state and local dignitaries attended the grand opening of the new Ideal Organization devoted to Ventura and Santa Barbara Counties

Some 4,000 Scientologists and federal, state and local dignitaries attended the grand opening of the new Ideal Organization devoted to Ventura and Santa Barbara Counties

Mr. Miscavige leads the dedication ceremony in Ventura County, Southern California, for a new Scientology Church to serve the hundreds of thousands who call these shores home.

Mr. Miscavige leads the dedication ceremony in Ventura County, Southern California, for a new Scientology Church to serve the hundreds of thousands who call these shores home.

Seaside Grand Opening of stunning new Church on Highway 101 marks a milestone for Scientology’s spectacular growth across the Golden State

Seaside Grand Opening of stunning new Church on Highway 101 marks a milestone for Scientology’s spectacular growth across the Golden State

For a complete list of new Ideal Churches of Scientology, visit Scientology.org/IdealChurches.

For a complete list of new Ideal Churches of Scientology, visit Scientology.org/IdealChurches.

The Church of Scientology cut the ribbon on a new Ideal Organization (Ideal Org), Saturday, February 22, 2020

The Church of Scientology cut the ribbon on a new Ideal Organization (Ideal Org), Saturday, February 22, 2020

Seaside Grand Opening of stunning new Church on Highway 101 marks a milestone for Scientology’s spectacular growth across the Golden State.

I see this not only as expansion in California but as an inspiration nationally for our Church and for our outreach programs helping with drug and human rights education and better moral choices.”

— Rev. Lee Holzinger

WASHINGTON, DC, USA, February 26, 2020 /EINPresswire.com/ — Riding a never-ending swell of expansion for the religion, the Church of Scientology cut the ribbon on a new Ideal Organization (Org), Saturday, February 22, along this slice of surfing paradise. The first Ideal Org devoted to Ventura and Santa Barbara Counties opened before an exuberant audience of some 4,000 Scientologists and federal, state and local dignitaries. The dedication crests an ambitious period of growth through the past decade, only accelerating into 2020.

For the 100,000 daily commuters motoring on the 101, the glass-encased, new Church gleams as an unmistakable beacon of freedom just minutes from Downtown Ventura and Surfers Point, and but 500 yards from the San Buenaventura State Beach. At 66,000 square feet, the expansive and striking structure provides the capacity to immediately multiply manyfold the Church’s outreach and services to the hundreds of thousands who call this stretch of coastline home.
Stirred by a wafting Pacific breeze, a festive air of accomplishment pervaded the occasion. Leading the grand celebration was Mr. David Miscavige, the ecclesiastical leader of the Scientology religion, who told the assembled that the wave for which they were waiting was now about to break: “A perfect wave. An endless wave. A wave anyone can ride to higher plateaus of ability and spiritual immortality. But, of course, not everyone knows where the shoreline ends and the ride of a lifetime begins—which is where you come in with an invitation to freedom and a lesson on how to catch that wave and never be the same again.”

Joining the Scientology parishioners and Church officials were Councilman Steven Gama, from the City of Port Hueneme, Ventura County; Sharon Byrne, Advisor to the 4th District of Santa Barbara County; John Chavez, Voluntary Agency Liaison, Federal Emergency Management Agency (FEMA); and Barbara Gaughen-Muller, President of the Tri-County United Nations Association.

In highlighting the Church’s work toward environmental responsibility, Councilman Gama described L. Ron Hubbard’s nonreligious moral guide, The Way to Happiness, as having “the power to get people into action.” He went on to state: “Your Way to Happiness volunteers have already been out with us all along Ormond Beach at our cleanups. From early morning until we’re done for the day, you are there taking care of our precious environment and helping it to thrive… So not only with this new Church help preserve all that is good about our incredible home, it will be beacon inspiring an even better environment, better neighbors and a better community for us all.”

Sharon Byrne of Santa Barbara County praised the impact regional Scientology-sponsored drug education has had on raising awareness and ultimately saving young lives. “Your film The Truth About Drugs provides the vision and guidance people need in 2020,” she said. “It gets in your face and tells it like it is. That’s precisely why it works. And why, with the Truth About Drugs program here in our Tri-County high schools, students are already saying, ‘I would never have smoked marijuana if I had seen this film, and I’m not going to do it again.’… So, one by one, you are helping realize an altogether new premise. You are helping shepherd our kids so no child will ever go down the path of taking drugs.”

John Chavez, Voluntary Agency Liaison for FEMA, acknowledged the many Scientology Volunteer Ministers in the audience, honoring their dedication to local recovery efforts in the wake of the Ventura fires. “When you’re dealing with a crisis of this magnitude,” he stated, “you need strong community and church support. And the Volunteer Ministers were there. You were on the ground in Ventura City. You were there in Ojai. You were at the side of firemen and distributing masks in the streets. You stayed right to the very end. You are a crucial link in our disaster response chain. In fact, I’ve got you right on my speed dial.”

No less laudatory was Barbara Gaughen-Muller, President of the Tri-County United Nations Association citing the Church’s tireless dedication to human rights education, inspiring forums and workshops through area charter schools and nonprofits. In light of Scientology Founder L. Ron Hubbard’s enduring commitment to upholding human rights, Ms. Gaughen-Muller proclaimed: “Seventy-five years ago, the prophecy for the UN was that: Housed within its unique glass building, there was a power that would change the world. Well, you now have your own beautiful glass home here, where all-the-world will see you. Your presence is powerful. And so on the eve of your Founder’s Birthday Celebration, let us now say, ‘Yes, Mr. Hubbard, here is a house of eternal freedom to transform lives all across this Golden Coast!’”

Church members from around the country traveled to Ventura to be part of the grand opening, including Reverends Lee and Kay Holzinger who had been ministers at that church for over 24 years. The Holzingers, who are currently executives at the Church of Scientology National Affairs Office, travelled from Washington, DC, just for the opening ceremony. “It was exhilarating to be there to fully experience this monumental achievement. I see this not only as expansion in California but as an inspiration nationally for our Church and for our outreach programs helping with drug and human rights education and better moral choices,” said Rev. Lee Holzinger.

The striking new facility provides the region with an introduction to Dianetics and Scientology, beginning with the Public Information Center. Its displays, containing more than 500 films, present the beliefs and practices of the Scientology religion and the life and legacy of Founder L. Ron Hubbard. The Information Center also offers a detailed overview of the many Church-sponsored humanitarian programs—including a worldwide human rights education initiative, far-reaching drug education, prevention and rehabilitation programs; a global network of literacy and learning centers; and the Scientology Volunteer Minister program, which has become one of the world's largest independent relief forces. The Center is open morning to night for visitors to tour at their leisure and return as often as they wish.

The Church’s Chapel provides for Scientology congregational gatherings, including Sunday Services, Weddings and Naming Ceremonies – as well as a host of events open to members of all faiths in the name of community collaboration. The new Church further includes multiple seminar rooms and classrooms, in addition to dozens of rooms for Scientology auditing (spiritual counseling.)

Ideal Church Organizations (called “Ideal Orgs”) realize the fulfillment of Founder L. Ron Hubbard's vision for the religion. They not only provide the ideal facilities to service Scientologists on their ascent to greater states of spiritual awareness and freedom, but are also designed to serve as a home for the entire community and a meeting ground for cooperative efforts to uplift citizens of all denominations.

This past decade has seen the opening of new Ideal Orgs across the US, including New York City, Harlem, Buffalo, Washington, DC, Atlanta, Tampa, Orlando, Miami, Nashville, Cincinnati, Columbus, Detroit, Twin Cities, Kansas City, Dallas, Denver, Salt Lake City, Phoenix, Las Vegas, Portland and Seattle. The opening of Ventura's new Ideal Org marks the 12th to open in the state of California—Los Angeles, Sacramento, San Francisco, Los Gatos, San Jose, Silicon Valley, San Fernando Valley, Pasadena, Inglewood, Orange County and San Diego.

This era of explosive growth for the Scientology religion is further represented by the opening of new Ideal Church Organizations in major cities all over the world, including London, Birmingham and Dublin in the British Isles; throughout Europe in Brussels, Rome, Milan, Padova, Madrid, Berlin, Hamburg, Stuttgart, Copenhagen, Malmö, Amsterdam, Basel and Budapest; in the Middle East at Tel Aviv; all along the Pacific Rim at Tokyo, Kaohsiung, Auckland, Sydney, Melbourne and Perth; in South Africa at Johannesburg and Pretoria; more in Canada at Québec and Cambridge; and in Latin American capitals of Mexico City and Bogotá.

For a complete list of new Ideal Churches of Scientology, visit Scientology.org/IdealChurches.

To disseminate Scientology's message still further and answer the overwhelming interest about the religion, the Church launched its own satellite TV channel, Scientology Network, on DIRECTV Channel 320, which also live streams at Scientology.tv, as well as on multiple platforms in 17 languages across 24 time zones.

Rev. Sue Taylor
National Affairs Office
+1 202-667-6404
email us here


Source: EIN Presswire

AFFINITY BIO PARTNERS EXPANDS BY LAUNCHING THE AFFINITY NETWORK

CHESTER SPRINGS, PENNSYLVANIA, UNITED STATES, February 26, 2020 /EINPresswire.com/ — AFFINITY BIO PARTNERS EXPANDS BY LAUNCHING THE AFFINITY NETWORK

(BUSINESS WIRE)—Affinity Bio Partners, LLC, a global clinical research organization focused on Medical Cannabis and CBD Clinical Research have launched the Affinity Network.

“We are very pleased with the expansion of Affinity Bio Partners, LLC with the launch of the Affinity Network. The Affinity Network is the “First of Its Kind” which developed a Certified, Best in Class, Pharmaceutical modeled infrastructure to assist business owners in the Medical Cannabis and CBD industry exceed their business goals. The Affinity Network has been established with qualified, fully vetted professional consultants and companies that are able to provide services globally which are in compliance with all applicable laws. As we continue to be the pioneers in the Medical Cannabis and CBD clinical research, artificial technology and patient advocacy industries it is critical for us to ensure that we are raising the bar from a professional standpoint. Together all of the companies within the Affinity Network will make a difference and continue to pave the way in the Medical Cannabis and CBD industries.”, stated Christina DiArcangelo, CEO and Founder, Affinity Bio Partners, LLC.

###
Affinity Bio Partners is a Clinical Research Organization (CRO) that provides best in class services while maintaining a personal approach. There are many CROs in the market, but there is only one that will give our client’s organization the attention, services and results. For more information on the company or general inquiries, please email: info@affinitybiopartners.com or visit us at www.affinitybiopartners.com or https://www.affinitybiopartners.com/affinity-network. Follow us on twitter at inf03006608, Facebook, LinkedIn and Instagram.

Christina DiArcangelo
Affinity Bio Partners, LLC
+1 408-857-0483
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn


Source: EIN Presswire

Kehoe Law Firm, P.C. Investigating Potential Securities Law Violations on Behalf of TUP Investors

Kehoe Law Firm, P.C.

Kehoe Law Firm, P.C.

Securities Class Action Lawsuit Filed Against Tupperware Brands Corporation – TUP Investors Encouraged to Contact Kehoe Law Firm, P.C.

PHILADELPHIA, PENNSYLVANIA, USA, February 26, 2020 /EINPresswire.com/ — Kehoe Law Firm, P.C. is investigating potential securities claims on behalf of shareholders of Tupperware Brands Corporation (“Tupperware” or the “Company”) (NYSE: TUP) resulting from allegations that Tupperware may have issued materially misleading business information to the investing public.

If you purchased, or otherwise acquired, Tupperware securities between January 30, 2019 and February 24, 2020 (the "Class Period"), you are encouraged to contact either Michael Yarnoff, Esq., (215) 792-6676, Ext. 804, myarnoff@kehoelawfirm.com, info@kehoelawfirm.com, or John Kehoe, Esq, (215) 792-6676, Ext. 801, jkehoe@kehoelawfirm.com, to learn more about the Tupperware securities investigation or your potential legal claims.

On February 25, 2020, a class action lawsuit was filed in United States District Court, Central District of California, against Tupperware Brands Corporation and other Company executives. According to the class action complaint, Defendants, allegedly, made false and/or misleading statements and/or failed to disclose that: (1) Tupperware lacked effective internal controls; (2) as a result, Tupperware would need to investigate Fuller Mexico’s accounting and liabilities; (3) consequently, Tupperware would be unable to timely file its annual report on Form 10-K for its fiscal year 2019; (4) Tupperware did not properly account for its accounts payable and accrued liabilities at Fuller Mexico; (5) Tupperware provided overvalued earnings per share guidance; (6) Tupperware would need relief from its $650 million Credit Agreement; and (7) as a result, Defendants’ public statements were materially false and/or misleading at all relevant times.

On February 24, 2020, post-market, Tupperware issued a press release announcing it will need an extension within which to timely file its annual report (Form 10-K) for the fiscal year ended December 28, 2019. Tupperware also announced it expects 2019 net earnings per share “in the range of breakeven to $0.34 versus $3.11 in the prior year[,]” and adjusted EPS of “$1.35-$1.70 versus $4.30 in the prior year.”

Tupperware said results were affected by "financial reporting issues in Fuller Mexico” and that Tupperware is “conducting an investigation primarily into the accounting for accounts payable and accrued liabilities at its Fuller Mexico beauty business[.]” Additionally, “[Tupperware] is forecasting a need for relief concerning its existing leverage ratio covenant in its $650 million Credit Agreement dated March 29, 2019 . . . to avoid a potential acceleration of the debt, which could have a material adverse impact on the Company.”

On this news, Tupperware’s stock price dropped significantly, and on February 25, 2020, Tupperware’s stock was down as much as 45%.

If you wish to discuss Kehoe Law Firm’s Tupperware securities investigation or have questions about your potential legal rights, please contact either John Kehoe, Esq, (215) 792-6676, Ext. 801, jkehoe@kehoelawfirm.com, or Michael Yarnoff, Esq., (215) 792-6676, Ext. 804, myarnoff@kehoelawfirm.com, info@kehoelawfirm.com, to learn more about the investigation or potential legal claims.

Kehoe Law Firm, P.C., with offices in New York and Philadelphia, is a multidisciplinary, plaintiff–side law firm dedicated to protecting investors from securities fraud, breaches of fiduciary duties, and corporate misconduct. Combined, the partners at Kehoe Law Firm have served as Lead Counsel or Co-Lead Counsel in cases that have recovered more than $10 billion dollars on behalf of institutional and individual investors.

John Kehoe, Esq.
Kehoe Law Firm, P.C.
+1 215-792-6676
email us here


Source: EIN Presswire

Janssen Pharmaceutical exclusive interview released ahead of Pre-filled Syringes East Coast

Pre-filled Syringes East Coast

Pre-filled Syringes East Coast 2020

SMi Reports: Alie Jahangir from Janssen Pharmaceutical to speak at Pre-Filled Syringes East Coast returning to Boston USA, in April.

LONDON, UNITED KINGDOM, February 26, 2020 /EINPresswire.com/ — With SMi’s highly sought after Pre-Filled Syringes East Coast conference taking place on April 27th and 28th for its 7th year in Boston, the event is guaranteed to bring together specialists within the industry to provide an exclusive insight into the sphere of regulation, new digital technology trends, human studies and innovative design and delivery systems within the prefilled syringe industry and more.

Ahead of the conference, SMi Group has caught up with Janssen Pharmaceutical’s Senior Manager, Alie Jahangir to discuss his insight and on the Pre-filled syringes market as well as his presentation on day-one of the two-day conference.

For those interested in attending, there is a $200 Early Bird discount on bookings expiring on February 28th, 2020. Places can be reserved at www.pfsamericas.com/einpr7

Snapshot of Alie’s interview:

What current topic will you be addressing in your presentation and what would you say makes it relevant to 2020?

“My talk will be focusing on new stability paradigm for combination products, including PFS as single-entity CP/ The major challenges in this industry for manufacturers, as indicated earlier, includes the interaction of PFS with the drug products. This causes great concern because it creates stability issues. Manufacturers need to eliminate the interaction between drugs and packaging materials. Regulatory bodies companies and customers will scrutinize and look carefully at every aspect of needle and syringe is specially as they are being used more and more today. Processing and quality control issues are therefore important period manufacturing costs are rising specially because of growing concern of needle stick injuries. Safety measures to eliminate needle stick injuries are major concern in the health care…”

How would you like to see the PFS USA market developing in the future and where do you think the biggest growth area will be in 2020?

“Given the advances in biologic market and specific requirement of such class of therapeutic products vis a vis volume and viscosity, a closer collaboration between therapeutic and device makers would create more opportunities to meet patients’ unmet needs. The biggest growth area would be in the area of wearables…”

The full interview, event details and speaker line-up are available to download on the website. The brochure can we downloaded at www.pfsamericas.com/einpr7

Pre-filled Syringes East Coast
Conference: April 27th-28th 2020
Post-conference workshop Day: April 29th

Sponsored by:
Almac | Aptar Pharma | Bold insight | CSS | Credence MedSystems | Mitsubishi Gas Chemical | Owen Mumford | PHC Corporation | Polyplastics-Topas | Steris | Weiss-Aug | Zeon Speciality Materials | Zwick Roell |
Contact Information:
For all media inquiries contact Jinna Sidhu on Tel: +44 (0)20 7827 6088 / Email: hsidhu@smi-online.co.uk

—ENDS—
About SMi Group:
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk

Jinna Drug Sidhu
SMi Group
02078276088
email us here


Source: EIN Presswire

Dr. Doosu Baik, DDS listed as Top Dentist in Cosmetic, Family & Implant Dentistry

Doosu Baik, DDS

Lynnwood, Washington Dentist Selected to the "America's Best Dentists" 2020 Directory

Dr. Doosu Baik Listed as Top Dentist for Cosmetic, Family & Implant Dentistry”

— TodaysBestDentists.com

LYNNWOOD, WASHINGTON, UNITED STATES, February 26, 2020 /EINPresswire.com/ — Lynnwood Washington dentist, Dr. Doosu Baik has been selected to the "America's Best Dentists" registry for 2020.

Selections were made by the National Consumer Advisory Board, an organization that identifies top professionals in their fields.

Services include: Dental Implants, Aesthetic Dentistry, Implant Assisted Overdentures, Cosmetic Veneers, Root Canal Therapy, Full and Partial Dentures and Full Mouth Rehabilitation.

Dr. Baik practices Cosmetic, Family & Implant Dentistry at 19720 68th Ave West, Suite A, in Lynnwood, WA 98036; serving patients in Seattle, Monroe, Lynnwood, East Washington and neighboring communities.

Dr. Baik received his Doctor of Dental Surgery degree (DDS), and then completed an Advanced Education in General Dentistry Residency program (AEGD), at the UCLA School of Dentistry. During his 17 years in practice, Dr. Baik has held several prestigious positions. He served as a Post-Doctoral Research Associate at the Burnett School of Biomedical Sciences at University of Central Florida College of Medicine. He was also a research fellow at the Division of Constitutive & Regenerative Sciences at UCLA School of Dentistry.

Dr. Baik is a member of the American Dental Association, Academy of Osseointegration, Washington State Dental Association and Seattle King County Dental Association.

For more information, please go to www.TodaysBestDentists.com or contact Dr. Doosu Baik, DDS directly at 360-794-0717.

The "National Consumer Advisory Board" accepts no fees, sponsorships, donations or advertising in their selection process. Dentists were chosen following an application based on training, experience, continuing education, and dedication to excellence. Only dentists that satisfy all the board's criteria can qualify for inclusion in the "Americas Best Dentists" directory.

TodaysBestDentists.com
Americas Best Dentists
+1 475-282-3043
email us here


Source: EIN Presswire

Maness Veteran Medical Adds Safersonic and EcoVue to the (MSPV) Medical/Surgical Prime Vendor Program

Maness Veteran Medical SDVOSB

Safersonic Ultrasound Probe Covers

EcoVue Ultrasound Gel

VAs Gain Access to Safersonic Ultrasound Transducer Covers & EcoVue Ultrasound Gel Through the MSPV Prime Vendor Program (Cardinal, Medline, Concordance, & AMD)

ASHEVILLE , NC , UNITED STATES , February 26, 2020 /EINPresswire.com/ — Maness Veteran Medical (MVM) is pleased to announce the addition to the MSPV program of two extremely popular brands: Safersonic Ultrasound Transducer Covers and the revolutionary new Ultrasound Gel, EcoVue®, manufactured by HR Pharmaceuticals. MVM strives every day to bring the world’s top products to veterans and has been at the forefront of cutting down delays of veteran access to new products. Through hard work and dedication, MVM has cut this time-frame down by years in some cases.

These two brands in particular are highly sought after within the VA and DoD. With a focus on infection control, quality, and cost reduction, these products bring great value to all parties involved.

Safersonic Ultrasound Transducer Covers are highly sought after due to their exceptional design, quality, and ease of us. They eliminate the need for gel under the transducer cover, preserving probes and cutting down on clean up time. Infection control remains a vital focus in the VA and DoD facilities alike. Safersonic satisfies that need, while also reducing capital equipment costs. Safersonic also is the only brand offering a one-foot probe cover, perfect for wireless probes.

EcoVue® may be relatively new to the ultrasound industry, but HR Pharmaceuticals (HR), its manufacturer is a mainstay in the medical field. As the manufacturer of Surgilube® surgical lubricant, an industry staple, HR takes intense pride in all they do. EcoVue® is no different. HR wanted to develop a new green and sustainable ultrasound gel with a keen focus on the environment and infection control. EcoVue® satisfies the FDA recommendation on not refilling ultrasound gel containers, thus eliminating the risk of cross contamination. EcoVue® allows the acoustic velocity to remain constant when heated to 40°C. Heat has little to no effect on performance and EcoVue® provides for a quick and easy clean-up and leaves no sticky residue. This amazing new product has quickly become a favorite of clinicians and patients alike.

Please explore the links within and reach out for samples today.

Johnathan Maness
Maness Veteran Medical
+1 727-452-5452
email us here
Visit us on social media:
LinkedIn


Source: EIN Presswire

Validation Consultant Connie Curts to be Featured on Close Up Radio

LEE'S SUMMIT, MISSOURI, UNITED STATES, February 26, 2020 /EINPresswire.com/ — Regulations compel due diligence to protect the public. Under FDA regulations, all healthcare related hardware, software, and instrumentation must go through a series of procedures to ensure it works consistently, accurately, can provide reliable raw data, and has strong electronic security to prevent changes or deletions. The combination of regulated procedures is referred to as “validation.”

Connie Curts is a validation consultant. She specializes in developing validation documentation for FDA-regulated equipment dedicated to pharmaceutical research.

“Everything that goes into a study to develop pharmaceuticals needs to be accurate, so all procedures must be followed specifically without deviation,” says Connie. “What I do is create the documents to define the intended usage for clients. There are user requirements against which you'd test the system to determine its accuracy. I create those test protocols, somebody else executes those protocols, and yet another person is reviewing the results to make sure the system demonstrates its performance.”

An IT professional by trade with a background in engineering, Connie develops the documentation for completeness and clarity, so clients know what they need to do to remain in compliance and everything is handled consistently and tracked through chain of custody.

“It's a tremendously complicated process, which is partly why drugs, especially new drugs, are so expensive,” says Connie. “With validation, you have to be very careful because in the long run, as with everything in health care, a patient's life could be at stake.”

When the FDA comes in and does an audit of a new system, they want to see all necessary due diligence.

“Sometimes it can be contentious with the FDA,” says Connie, “but I tend to believe that most people really are trying to do their best and be as detailed and accurate as possible. They are as concerned for the patient as much as anyone.”

Connie says she has always been fascinated by mathematics. She holds a bachelor's degree in electronics engineering technology through Missouri Institute of Technology. As the computer age changed and industries changed, her career evolved to focus on regulations in one industry.

“I prefer to tinker with things, make them work, debug them,” says Connie. “I also love teaching and giving back to the next generation, everything I could about my experiences and best practices for good laboratory procedure.”

She was one of 95 international collaborators on the book entitled Computerized Systems Used in Nonclinical Safety Assessment: Current Concepts in Validation and Compliance.

Close Up Radio will feature Connie Curts in an interview with Jim Masters on February 28th at 2pm EST

Listen to the show on BlogTalkRadio

If you have any questions for our guest, please call (347) 996-3389

Lou Ceparano
Close Up Radio
+1 (631) 850-3314
email us here
Visit us on social media:
Facebook


Source: EIN Presswire

Blockchain in Healthcare Market to Grow at Staggering 70% CAGR until 2027 – TechSci Research

Blockchain in Healthcare Market

Need to safeguard patient healthcare data and surging cyberattacks to drive global blockchain in healthcare market through 2027

NEW YORK, NEW YORK, UNITED STATES, February 26, 2020 /EINPresswire.com/ — Need to safeguard patient healthcare data and surging cyberattacks to drive global blockchain in healthcare market through 2027

According to TechSci Research report, “Global Blockchain in Healthcare Market By Type, By Application, By End User, By Region, Competition, Forecast & Opportunities, 2027”, global blockchain in healthcare market is projected to witness a CAGR of over 70% during 2020 – 2027, on account of increasing cases of data breaches in the healthcare industry. The implementation of blockchain in healthcare industry will provide transparency on complex transactions existing between different stakeholders of clinical supply chain. Additionally, blockchain helps to manage healthcare related data without alteration, which is anticipated to drive the blockchain in healthcare market through 2027. Need for improving security and interoperability of healthcare information system is boosting the adoption of blockchain in healthcare industry.

Browse 15 market data Tables and 85 Figures spread through 110 Pages and an in-depth TOC on "Global Blockchain in Healthcare Market”

https://www.techsciresearch.com/report/blockchain-in-healthcare-market/3913.html

The global blockchain in healthcare market, globally, can be segmented based on type, application, end-user and region. Based on end user, the market can be segmented into healthcare providers, pharmaceutical companies and others. Major healthcare markets such as the US and Europe have mandated the implementation of full trace and tracking of pharma products, owing to which they account for the leading share in the market. Blockchain in healthcare market is at a nascent stage and finds applications in drug supply chain management, clinical data exchange & interoperability, claims adjudication & billing management, prescription drug abuse and others. Increasing number of counterfeit drugs in circulation and implementation of strict regulations, such as Drug Quality and Security Act (DQSA) and Falsified Medicines Directive (FMD) in the US and Europe are contributing to the leading share of drug supply chain management segment.

Download Sample Report @ https://www.techsciresearch.com/sample-report.aspx?cid=3913

Customers can also request for 10% free customization on this report.

IBM Corporation, Microsoft Corp., Accenture Plc, PokitDok, Inc., Factom Inc., Healthereum, LLC, Guardtime, Proof.Work, Simplyvital Health and Farmatrust are some of the leading market players. Companies operating in the market are using organic strategies such as product launches, mergers and collaborations to boost their share. In 2018, IBM launched a low-cost platform to encourage the adoption of blockchain in healthcare industry.
“North America is the leading region in global blockchain in healthcare market, backed by technological advancements and regulations in place for the safety of patient data and delivery of best healthcare services. Moreover, high need for reducing healthcare costs and preventing tampering of medical data is likely to boost demand for blockchain in healthcare in the region over the course of next five years.”, said Mr. Karan Chechi, Research Director with TechSci Research, a research based global management consulting firm.

“Global Blockchain in Healthcare Market By Type, By Application, By End User, By Region, Competition, Forecast & Opportunities, 2027” has evaluated the future growth potential of global blockchain in healthcare market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges and opportunities in global blockchain in healthcare market.

About TechSci Research

TechSci Research is a leading global market research firm publishing premium market research reports. Serving 700 global clients with more than 600 premium market research studies, TechSci Research is serving clients across 11 different industrial verticals. TechSci Research specializes in research based consulting assignments in high growth and emerging markets, leading technologies and niche applications. Our workforce of more than 100 fulltime Analysts and Consultants employing innovative research solutions and tracking global and country specific high growth markets helps TechSci clients to lead rather than follow market trends.

Contact

Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York – 10017

Tel: +1-646-360-1656

Email: sales@techsciresearch.com

New Age TechSci
New Age TechSci Research Pvt Ltd
+ +1 646 360 1656
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn


Source: EIN Presswire

PERTHERA AND LAZAREX CANCER FOUNDATION ANNOUNCE PARTNERSHIP TO ADVANCE PRECISION ONCOLOGY INITIATIVES

Lazarex and Perthera unite to advance Clinical Trial Access and Enrollment for Cancer Patients

HOLLISTON, MA, USA, February 26, 2020 /EINPresswire.com/ — Perthera, Inc., a Biohealth Informatics company with an Oncology Platform proven to advance patient outcomes, and Lazarex Cancer Foundation, an advocacy group whose mission is to improve patient access to cancer clinical trials, have announced the launch of their partnership today. Together, they will be focused on matching and enrolling patients in clinical trials through Lazarex’s IMPACT and CARE programs, by utilizing Perthera’s treatment-matching Artificial Intelligence (AI) technology and other elements of the Perthera Platform to advance precision medicine for cancer patients.

“We are excited to work with Lazarex Cancer Foundation, a leading organization dedicated to advancing and accelerating patient enrollment in clinical trials,” said Gary Gregory, CEO of Perthera, Inc. “Lazarex’s passion and mission align perfectly with our innovative technology Platform. Together, we form a powerful team to make a difference for patients, physicians and clinical trial sites.”

Perthera’s proprietary AI technology allows physicians to utilize comprehensive patient informatics, such as medical history and molecular profile information, to equip physicians with precisely matched therapies that are best suited to advance patient outcomes. Through Perthera’s partnership with Lazarex, patients will be matched to the most relevant clinical trials, while expanding patient access and clinical trial enrollment.

"Perthera’s Platform has been proven to advance patient outcomes from both an overall and progression-free survival perspective, and also proven to accelerate Clinical Trial enrollment by five times the national average,” said Dana Dornsife, Founder and Chairman of Lazarex Cancer Foundation. “Perthera’s exceptional capabilities are aligned with the broad reach of our CARE and IMPACT programs and this positions both organizations to deliver exemplary value to patients, physicians and our clinical trial sites across the country.”

According to the Journal of the National Cancer Institute, only 2%-4% of newly diagnosed patients participate in clinical trials. Unfortunately, finances and transportation tend to be the largest barriers in the way of these enrollments. Forbes notes that because of low enrollment, many clinical trials do not meet their targets, resulting in a significant barrier to the advancement of cancer research. Lazarex, founded by members who recognized this significant issue, provides education to patients and has created supportive programs to promote higher patient enrollment in clinical trials.

Perthera’s partnership with Lazarex aims to utilize its proven, proprietary Platform to increase clinical trial enrollment and generate real-world evidence to advance cancer research & development. To reach out to Perthera regarding their Platform and matched treatment recommendations for oncologists and patients, contact Hope@Perthera.com or call (833) 781-7810.

If you are a cancer patient, a caregiver or friend of a cancer patient interested in patient resources or learning more about the possibility of participating in a clinical trial, visit the Lazarex Cancer Foundation’s website to learn more about your options https://lazarex.org/.

About Perthera, Inc.
Perthera is the leading Therapeutic Intelligence company advancing cancer care outcomes through its Precision Oncology Platform. Their innovative technology precisely matches cancer patients with ranked therapeutic options and has been utilized at over 250+ cancer care sites and utilized by over 10% of US Oncologists. Their Precision Oncology Platform, with an AI-driven Therapeutic Intelligence Engine™, has been clinically proven to extend overall and progression-free survival rates by over two-fold for cancer patients. Perthera positions Hospitals and Physicians to harness the power of Precision Medicine to improve patient outcomes and save lives. The Perthera Platform also offers a highly comprehensive Precision Cancer database and an array of services that delivers significant value to Pharma, Drug Development, Clinical Research Organizations and Payers.

About Lazarex Cancer Foundation
Lazarex Cancer Foundation is a publicly funded 501(c)(3) charity focused on the improvement of outcomes in cancer care, giving hope, dignity, and life to advanced-stage cancer patients and the medically underserved by providing assistance with costs for FDA clinical trial participation, identification of clinical trial options, community outreach and engagement. In its 14 years, Lazarex has assisted over 5,500 patients in clinical trials.
Learn more about Lazarex at https://lazarex.org/. For any media inquiries about the Lazarex Foundation, contact Laura Evans Manatos at +1.301.379.6028 and Laura@LauraEvansMedia.com.

Gary L. Gregory
Perthera, Inc.
+1 508-397-8885
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn


Source: EIN Presswire

Oncology Biosimilar Market Size to be Worth 13,993.64 Million by 2024 – Zion Market Research

Oncology Biosimilar Market

Oncology Biosimilar Market

Oncology Biosimilar Market expected to generate revenue of around USD 13,993.64 million by end of 2024, growing at a CAGR of around 26.8% between 2018 and 2024

Oncology Biosimilar Market To Report Impressive Growth, Revenue To Surge To US$ 13,993.64 Million By 2024”

— Zion Market Research

NEW YORK, NEW YORK, UNITED STATES, February 26, 2020 /EINPresswire.com/ — Zion Market Research has published a new report titled “Oncology Biosimilar Market by Cancer Type (Breast Cancer, Colorectal Cancer, Blood Cancer, Neutropenia Cancer, Non-Small Cell Lung Cancer, and Others), By Drug Type (mAb, Immunomodulators, Hematopoietic Agents, G-CSF, and Others), By Distribution Channel (Retail Pharmacies, Hospital Pharmacy, and Online Pharmacy): Global Industry Perspective, Comprehensive Analysis and Forecast, 2017 – 2024”. According to the report, global oncology biosimilar market was valued approximately USD 2655.19 million in 2017 and is expected to generate revenue of around USD 13,993.64 million by end of 2024, growing at a CAGR of around 26.8% between 2018 and 2024.

Biosimilar is the identical copy of oncology biologics used for the treatment of cancer and officially approved for the treatment of cancer. These molecules are cost-effective, efficient, and have the same ability as biologics. These molecules are easy to manufacture as compared to biologics and can only be manufactured after patent expiry. Earlier there were various patented biologics available in the market but nowadays most of the patents have expired and few are on the verge of patent expiry. In the past few years, various biosimilars have been approved by FDA for the treatment of various types of cancer such as blood cancer, colorectal cancer, breast cancer, and others. In the near future, it is expected that a few more biosimilars will be introduced in the market thus supporting the growth of the market.

Get Free Research Report Sample PDF – https://www.zionmarketresearch.com/requestbrochure/oncology-biosimilar-market

Oncology biosimilar market is primarily driven by the increased prevalence of cancer, which has led to the increased demand for affordable therapies for the treatment of cancer. There are various pharmaceutical companies available in the market which are involved in the manufacturing of biosimilar. Patent expiry is also one of the major driving factors for the oncology biosimilar market. Patent expiry will provide an opportunity to the pharmaceutical companies to manufacture more biosimilars which will fuel the market growth in the near future. Increased demand for the healthcare facilities and rapid approval of biosimilars will support the growth of oncology biosimilar market in the near future.

Oncology biosimilar market is segmented on the basis of different types of cancer such as breast cancer, colorectal cancer, blood cancer, neutropenia cancer, non-small cell lung cancer, and others. On the basis of drug type, the market is segmented into mAb, immunomodulators, hematopoietic agents, G-CSF, and others. G-CSF is expected to grow at the fastest rate in the global market over the forecast period. On the basis of the distribution channel, the market is segmented into retail pharmacies, hospital pharmacy, and online pharmacy. Hospital pharmacy is expected to grow at the fastest rate over the forecast period.

Browse full Report TOC for more Industry Insights – https://www.zionmarketresearch.com/toc/oncology-biosimilar-market

North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa are key regional segments of global oncology biosimilar market. North America is anticipated to remain the leading region over the forecast period. Demand for oncology biologics was highest in North America especially in the U.S. Asia Pacific is expected to be the fastest growing region in the oncology biosimilar market during the forecast period. Moreover, the Middle East and Africa and Latin America are also expected to show considerable growth for this market in the years to come.

Some of the key players in oncology biosimilar market include Teva Pharmaceutical Industries Ltd., Biocon, STADA Arzneimittel AG, Sandoz International GmbH, Intas Pharmaceuticals Ltd., Celltrion Inc., Pfizer Inc., Apotex Inc., Dr. Reddy’s Laboratories Ltd., and BIOCAD, among others.

This report segments the global oncology biosimilar market as follows:

Global Oncology Biosimilar Market: Test Type Segment Analysis:

Breast Cancer
Colorectal Cancer
Blood Cancer
Neutropenia Cancer
Non-Small Cell Lung Cancer
Others

Global Oncology Biosimilar Market: Drug Type Segment Analysis:

mAb
Immunomodulators
Hematopoietic Agents
G-CSF
Others

Global Oncology Biosimilar Market: Distribution Channel Analysis:

Retail Pharmacies
Hospital Pharmacy
Online Pharmacy

Global Oncology Biosimilar Market: Regional Analysis:

North America
The U.S.
Europe
UK
France
Germany
Asia Pacific
China
Japan
India
Latin America
Brazil
The Middle East and Africa

Browse Press Release: https://www.zionmarketresearch.com/news/oncology-biosimilar-industry

About Us:

Zion Market Research is an obligated company. We create futuristic, cutting-edge, informative reports ranging from industry reports, the company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client’s needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us.

Contact Us:
Zion Market Research
244 Fifth Avenue, Suite N202
New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll-Free No.1-855-465-4651
Email: sales@zionmarketresearch.com
Website: https://www.zionmarketresearch.com

Kalpesh Deshmukh
Zion Market Research
+1 855 465 4651
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn


Source: EIN Presswire